A Nobel laureate MIT professor and a medtech exec talk up how COVID-19 has reshaped attitudes toward public health, fiscal policy, and the state’s economic role, and of how demands for greater supply-chain resilience and autonomy in making medicines have spawned the concept of ‘life-science sovereignty.’